Drug Spending in General, Insulin in Particular Raise Ire of the Public

It’s certainly no secret that the escalation in drug costs over the past few years has caught the attention–and raised the angst–of many sectors of the public dependent on medicine. But one product in particular–the Epipen–generated an incredible amount of controversy last year. In fact, insulin in general has seen a doubling in price over the past five years, with co-pays and related fees showing even greater increases in recent years. The issue is discussed in an article by Carisa Scott posted on kdvr.com. Check it out here…

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.